

General Assembly

Committee Bill No. 5

February Session, 2016

LCO No. 3035



Referred to Committee on FINANCE, REVENUE AND BONDING

Introduced by: (FIN)

AN ACT ESTABLISHING A SURCHARGE ON THE MANUFACTURE AND DISTRIBUTION OF OPIOIDS AND FUNDING FOR OPIOID ABUSE PREVENTION AND TREATMENT.

Be it enacted by the Senate and House of Representatives in General Assembly convened:

- 1 Section 1. (NEW) (Effective January 1, 2017) (a) For the purposes of
- 2 this section and section 2 of this act:
- 3 (1) "Commissioner" means the Commissioner of Revenue Services;
- 4 (2) "Controlled substance" means a controlled substance, as defined
- 5 in section 21a-240 of the general statutes, in schedule II, or III, IV or V
- 6 that is also an opioid;
- 7 (3) "Manufacturer" means a manufacturer of a controlled substance
- 8 to be sold in this state, and includes, but is not limited to, a
- 9 manufacturer of a controlled substance that is licensed in accordance
- 10 with section 21a-246 of the general statutes;
- 11 (4) "Opioid" shall include opium, opiate, opium derivatives and
- 12 opium poppy;

LCO No. 3035 1 of 8

- 13 (5) "Pharmacist" means a person authorized by law to practice 14 pharmacy pursuant to section 20-590, 20-591, 20-592 or 20-593 of the 15 general statutes;
- (6) "Pharmacy" means an establishment licensed pursuant to section
 20-594 of the general statutes; and

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

- (7) "Wholesaler" means a wholesaler, as defined in section 21a-240 of the general statutes, of a controlled substance to be sold in this state, and includes, but is not limited to, a wholesaler of a controlled substance that is licensed in accordance with section 21a-246 of the general statutes.
- (b) There shall be paid to the Commissioner of Revenue Services by each manufacturer or wholesaler of a controlled substance a surcharge at a rate of six and thirty-five-hundredths per cent on its gross receipts for any controlled substance lawfully sold on or after January 1, 2017, to any of the following named persons located in this state: (1) A pharmacist or pharmacy; (2) a physician, dentist or veterinarian; (3) a person in charge of a hospital, incorporated college or scientific institution; (4) a person in charge of a laboratory; or (5) a registrant, as defined in subdivision (47) of section 21a-240 of the general statutes, who is permitted to purchase and possess such controlled substance under federal and state laws and regulations. Such manufacturer or wholesaler may itemize and collect the amount of such surcharge on any sale to a person described in subdivisions (1) to (5), inclusive, of this subsection. Any person described in subdivisions (1) to (5), inclusive, of this subsection who dispenses such controlled substance within this state to a beneficiary of the Medicare Part D program as a covered benefit under the Medicare Part D program, or to a beneficiary of any other program under which such controlled substance is a covered benefit that is exempt from taxation, may claim a refund of the amount of such surcharge with respect to such beneficiary in accordance with section 2 of this act.
 - (c) Each manufacturer or wholesaler of controlled substances that

LCO No. 3035 **2** of 8

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

(d) Each manufacturer and wholesaler shall submit a return quarterly to the Commissioner of Revenue Services, applicable with respect to the calendar quarter beginning January 1, 2017, and each calendar quarter thereafter, on or before the last day of the month immediately following the end of each such calendar quarter, on a form prescribed by the commissioner, together with payment of the quarterly surcharge determined and payable in accordance with the provisions of this section. Whenever such surcharge is not paid when due, a penalty of ten per cent of the amount due or fifty dollars, whichever is greater, shall be imposed, and such surcharge shall bear interest at the rate of one per cent per month or fraction thereof until the same is paid. The Commissioner of Revenue Services shall cause copies of a form prescribed for submitting returns as required under this section to be distributed to persons subject to the surcharge. Failure to receive such form shall not be construed to relieve any manufacturer or wholesaler subject to the surcharge under this section from the obligations of submitting a return, together with payment of such surcharge within the time required. The provisions of sections 12-548 to 12-554, inclusive, of the general statutes and sections 12-555a and 12-555b of the general statutes shall apply to the provisions of this

LCO No. 3035 3 of 8

section in the same manner and with the same force and effect as if the language of said sections 12-548 to 12-554, inclusive, and sections 12-555a and 12-555b had been incorporated in full into this section and had expressly referred to the surcharge imposed under this section, except to the extent that any such provision is inconsistent with a provision of this section. Any moneys received by the commissioner pursuant to this section shall be deposited into the opioid abuse prevention and treatment account established in section 3 of this act.

- (e) The Commissioner of Revenue Services shall notify the Commissioner of Consumer Protection whenever a manufacturer or wholesaler licensed pursuant to section 21a-246 of the general statutes has continuously failed to comply with the requirements of this section for a period of at least six months. The Commissioner of Consumer Protection may suspend, revoke or refuse to renew the license of a manufacturer or wholesaler who has continuously failed to comply with the requirements of this section for a period of six months or longer. The Commissioner of Revenue Services shall notify the licensing authority of any other state where a manufacturer or wholesaler has continuously failed to comply with the requirements of this section for a period of at least six months.
- (f) Nothing in this section shall exempt any person from the tax imposed pursuant to chapter 228d of the general statutes with respect to marijuana or other controlled substance, as those terms are defined in section 12-650 of the general statutes.
- Sec. 2. (NEW) (Effective January 1, 2017) (a) Any person claiming a refund pursuant to subsection (b) of section 1 of this act shall file such claim in accordance with this section. Each claim for a refund shall be on a form prescribed by the Commissioner of Revenue Services and shall be accompanied by invoices or sales receipts or other statements of fact, under penalty of false statement, showing, to the satisfaction of the commissioner, the amount paid with respect to such refund, and

LCO No. 3035 **4** of 8

any other information that is deemed necessary by the commissioner 112 for the determination of such claim. Any claim for a refund with 113 respect to a controlled substance sold by such person during any 114 calendar year shall be filed with the commissioner on or before May 115 thirty-first of the succeeding year.

111

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132 133

134

135

136

137

138

139

140

141

142

- (b) (1) The commissioner shall, not later than ninety days after receipt of any claim under this section, transmit all claims approved by the commissioner to the Comptroller, who shall draw an order upon the State Treasurer for payment. If the commissioner determines that any such claim is not valid, either in whole or in part, the commissioner shall mail notice of the proposed disallowance to the claimant and such notice shall set forth briefly the commissioner's findings of fact and the basis of disallowance in each case decided in whole or in part adversely to the claimant. Sixty days after the date on which it is mailed, a notice of proposed disallowance shall constitute a final disallowance except only for such amounts as to which the claimant has filed, as provided in subdivision (2) of this subsection, a written protest with the commissioner.
- (2) On or before the sixtieth day after the mailing of the proposed disallowance, the claimant may file with the commissioner a written protest against the proposed disallowance in which the claimant sets forth the grounds on which the protest is based. If a protest is filed, the commissioner shall reconsider the proposed disallowance and, if the claimant has so requested, may grant or deny the claimant or the claimant's authorized representatives an oral hearing.
- (3) The commissioner shall mail notice of the commissioner's determination to the claimant, which notice shall set forth briefly the commissioner's findings of fact and the basis of decision in each case decided in whole or in part adversely to the claimant.
- (4) The action of the commissioner on the claimant's protest shall be final upon the expiration of one month from the date on which the commissioner mails notice of the commissioner's action to the claimant

LCO No. 3035 **5** of 8 unless within such period the claimant seeks judicial review of the commissioner's determination in the manner provided for distributors

pursuant to section 12-463 of the general statutes.

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

Sec. 3. (NEW) (Effective January 1, 2017) There is established an opioid abuse prevention and treatment account which shall be a separate, nonlapsing account within the General Fund. The account shall contain the amount of any surcharges collected pursuant to section 1 of this act and any other moneys required by law to be deposited in the account. Amounts in the account shall be expended only for the purpose of providing funds to the Department of Mental Health and Addiction Services to provide grants-in-aid for regional opioid abuse prevention and treatment programs pursuant to section 5 of this act.

- Sec. 4. Subsection (d) of section 17a-450 of the general statutes is repealed and the following is substituted in lieu thereof (*Effective January 1, 2017*):
- (d) The Department of Mental Health and Addiction Services is designated as the lead state agency for substance abuse prevention and treatment in this state, and as such is designated as the state methadone authority. As the designated state methadone authority, the department is authorized by the federal Center for Substance Abuse Treatment of the Substance Abuse and Mental Health Services Administration within the United States Department of Health and Human Services to exercise responsibility and authority for the treatment of opiate addiction with an opioid medication, and specifically for: (1) Approval of exceptions to federal opioid treatment protocols in accordance with the Center for Substance Abuse Treatment, (2) monitoring all opioid treatment programs in the state, (3) providing grants-in-aid to regional opioid abuse prevention and treatment programs that follow state and federal treatment protocols <u>in accordance with section 5 of this act</u>, and [(3)] (4) approval of Center for Substance Abuse Treatment certification of all opioid treatment

LCO No. 3035 **6** of 8

programs in the state. The Commissioner of Mental Health and Addiction Services may adopt regulations in accordance with chapter 54 to carry out the provisions of this subsection.

Sec. 5. (NEW) (Effective January 1, 2017) (a) The Commissioner of Mental Health and Addiction Services shall provide grants-in-aid, within available resources, to one or more regional opioid abuse prevention and treatment programs in each mental health region established pursuant to section 17a-478 of the general statutes. The commissioner shall provide such grants-in-aid to programs that follow state and federal treatment protocols and shall allocate such grants-in-aid on the basis of regional need and demand for services. Each program that receives a grant-in-aid pursuant to this section shall provide services in a manner that reduces the stigma associated with opioid abuse prevention and treatment and minimizes client contact with the criminal justice system.

(b) Not later than January 31, 2018, the commissioner shall submit a report to the joint standing committees of the General Assembly having cognizance of matters relating to public health and finance, revenue and bonding concerning the grants-in-aid awarded during the calendar year commencing January 1, 2017. The report shall indicate the amount of the grants-in-aid awarded, the recipients of the grants-in-aid, any amounts remaining in the opioid abuse prevention and treatment account established pursuant to section 3 of this act that were not allocated as of December 31, 2017, and the commissioner's recommendations, if any, for amendments to the general statutes regarding the grants-in-aid program or regional opioid abuse prevention and treatment programs.

This act sha	all take effect as follows	and shall amend the following
Section 1	January 1, 2017	New section
Sec. 2	January 1, 2017	New section
Sec. 3	January 1, 2017	New section

LCO No. 3035 **7** of 8

000000000000000000000000000000000000000	
17a-450(d)	
New section	

Statement of Purpose:

To establish a surcharge on the gross receipts of opioids sold in this state by manufacturers and wholesalers, establish an opioid abuse prevention and treatment account from the proceeds of the surcharge, and provide grants-in-aid to regional opioid abuse prevention and treatment programs that follow state and federal treatment protocols.

[Proposed deletions are enclosed in brackets. Proposed additions are indicated by underline, except that when the entire text of a bill or resolution or a section of a bill or resolution is new, it is not underlined.]

Co-Sponsors: SEN. CRISCO, 17th Dist.

January 1, 2017

January 1, 2017

S.B. 5

Sec. 4

Sec. 5

LCO No. 3035 **8** of 8